Pharming Group N.V. PHAR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -3.23% | -8.40% | 14.96% | 29.98% | 25.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.23% | -8.40% | 14.96% | 29.98% | 25.82% |
| Cost of Revenue | 62.12% | -20.17% | 73.05% | 3.70% | 12.42% |
| Gross Profit | -10.19% | -7.02% | 6.14% | 32.61% | 27.43% |
| SG&A Expenses | -15.59% | -20.19% | 8.82% | -2.04% | 6.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 22.99% | 1.57% | -143.36% | 90.86% | -102.74% |
| Total Operating Expenses | 7.93% | -10.19% | 27.87% | 0.88% | 6.68% |
| Operating Income | -87.90% | 30.28% | -74.18% | 531.01% | 447.61% |
| Income Before Tax | -57.06% | 59.67% | -28.12% | 742.60% | 11,898.33% |
| Income Tax Expenses | -44.56% | -85.19% | -113.83% | 104.43% | 118.39% |
| Earnings from Continuing Operations | -64.00% | 64.99% | 86.36% | 829.98% | 473.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.10% | 64.58% | 86.36% | 829.98% | 485.39% |
| EBIT | -87.90% | 30.28% | -74.18% | 531.01% | 447.61% |
| EBITDA | -77.87% | 59.77% | -67.91% | 251.12% | 1,131.26% |
| EPS Basic | -63.24% | 68.18% | 105.13% | 850.00% | 477.78% |
| Normalized Basic EPS | -56.72% | 62.96% | -84.85% | -- | 6,800.00% |
| EPS Diluted | -62.12% | 68.18% | 105.71% | 725.00% | 466.67% |
| Normalized Diluted EPS | -56.72% | 62.96% | -86.87% | -- | 6,800.00% |
| Average Basic Shares Outstanding | -2.97% | 11.31% | -10.47% | -2.85% | -0.37% |
| Average Diluted Shares Outstanding | -2.97% | 11.31% | 2.32% | -2.85% | -0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |